Real-Life Experience of Sorafenib Treatment for Hepatocellular Carcinoma in Korea: From GIDEON Data.
- Author:
Do Young KIM
1
;
Hye Jin KIM
;
Kwang Hyub HAN
;
Sang Young HAN
;
Jeong HEO
;
Hyun Young WOO
;
Soon Ho UM
;
Yeul Hong KIM
;
Young Oh KWEON
;
Ho Yeong LIM
;
Jung Hwan YOON
;
Wan Sik LEE
;
Byung Seok LEE
;
Han Chu LEE
;
Baek Yeol RYOO
;
Seung Kew YOON
Author Information
- Publication Type:Original Article
- Keywords: Hepatocellular carcinoma; Sorafenib; Korea
- MeSH: Carcinoma, Hepatocellular*; Diarrhea; Humans; Incidence; Korea*; Life Change Events; Prospective Studies; Skin
- From:Cancer Research and Treatment 2016;48(4):1243-1252
- CountryRepublic of Korea
- Language:English
- Abstract: PURPOSE: The purpose of this study is to report real life experiences of sorafenib therapy for hepatocellular carcinoma (HCC) in Korea, using a subset of data from GIDEON (Global Investigation of Therapeutic Decisions in HCC and of Its Treatment with Sorafenib; a large, prospective, observational study). MATERIALS AND METHODS: Between January 2009 and April 2012, a total of 497 patients were enrolled from 11 sites in Korea. Of these, 482 patients were evaluable for safety analyses. Case report forms of paper or electronic version were used to record safety and efficacy data from all patients. RESULTS: More patients of Child-Pugh A received sorafenib for > 8 weeks than did patients of Child-Pugh B (55.5% vs. 34.3%). Child-Pugh score did not appear to influence the starting dose of sorafenib, and approximately 70% of patients both in Child-Pugh A and B groups received the recommended initial daily dose of 800 mg (69.0% and 69.5%, respectively). The median overall survival (OS) and time to progression (TTP) were 8.5 months and 2.5 months. In Child-Pugh A patients, the median OS and TTP were 10.2 months and 2.5 months. The most frequent treatment-emergent drug-related adverse event was hand-foot skin reaction (31.7%), followed by diarrhea (18.0%). The incidence of treatment-emergent adverse events was similar in both Child-Pugh A (85.4%) and Child-Pugh B (84.8%) patients. CONCLUSION: Sorafenib was well tolerated by Korean HCC patients in clinical settings, and the safety profile did not appear to differ by Child-Pugh status. Survival benefit in Korean patients was in line with that of a previous pivotal phase III trial (SHARP).
